09:46 AM EST - Antibe Therapeutics Inc. : Provided an update on it second pipeline drug, ATB-352, a potent pain-killer intended for the relief of acute, severe pain. Recently completed pre-clinical studies have now demonstrated that ATB-352, unlike opiate drugs, does not bind to opioid receptors and therefore does not pose a risk of addiction. Antibe Therapeutics Inc.
shares V.ATE are trading unchanged at $0.20.
